Transplantation of small cord blood (CB) units, or of autologous ex vivo-genetically modified adult hematopoietic stem cells (HSC), face the common challenge of suboptimal HSC doses for infusion and impaired engraftment of the transplanted cells. Ex vivo expansion of HSCs, using either cellbased coculture approaches or especially small molecules have been successfully tested mainly in CB and in prolonged cultures. Here, we explored whether innovative combinations of small molecules can sufficiently, after short culture, expand adult HSCs while retaining their functionality in vivo. We found that 5-day cultured cells, in the presence of the small molecule combinations tested, achieved higher engraftment levels in NSG mice than both their uncultured and their cytokine only-cultured counterparts. Surprisingly, the engraftment levels were neither concordant to the numbers of phenotypically similar HSCs expanded under different small molecule combinations, nor explained by their distinct companion cells present. Transcriptomic comparative analysis of sorted, phenotypically similar, ex vivo generated HSCs transplanted in equal numbers, suggested that HSCs generated under expansion conditions that maintain low expression of the Rap1/Ras/ PI3K-AKT pathway exhibit a superior functional profile in vivo. STEM CELLS TRANSLATIONAL MEDI-CINE 2017;6:1852-1858 
INTRODUCTION
Successful hematopoietic stem cells (HSC) transplantation protocols have been associated with high numbers of donor cells. The need for large numbers of engraftable HSCs becomes particularly challenging in case of cord blood (CB)-transplantation because of the size of suitable grafts, and in adult HSC-gene therapy protocols, where the culture conditions may lead to impaired engraftment potential [1] . Even though long-term HSC cultures in cytokine supplemented medium can dramatically increase the numbers of immunophenotypically identified HSCs [2, 3] , the numbers of engraftable HSCs under these conditions can at best be maintained, and their functionality is largely compromised [2] . Methods to improve maintenance as well as expansion of the genetically modified cells, would enhance hematologic recovery in myeloablated patients and increase long-term in vivo engraftment of the modified graft, greatly improving the short-term safety and long-term efficacy of such protocols [4] .
Recently, high throughput screening of large chemical libraries identified a number of small molecules as potential new tools for HSC expansion. Some of the most promising molecules described, include the aryl hydrocarbon receptor (AHR) antagonist StemRegenin1 (SR1) [5] , the p38-MAPK14 inhibitor LY2228820 (Ly) [6] , and the pyrimidoindole derivative UM171 [7] . Expansion efforts using these molecules, however, have been focused on CB-HSCs, while their effects on adult HSCs have been less explored. In the present study, we compared these promising conditions, alone and in combinations, for expanding ex vivo, engraftable adult HSCs. To avoid loss of stemness of the expanded cells with prolonged cultures, we tested the different protocols in a short 5-day culture, which would likely be beneficial in a gene therapy setting.
MATERIALS AND METHODS
Mobilized peripheral blood CD341 cells from healthy donors were cultured for 5 days in serum free medium, supplemented with Fms related tyrosine kinase 3 (Flt-3), stem cell factor (SCF), and thrombopoietin (TPO) and in the presence of the small molecules SR1, Ly, and UM171, alone or in combinations; SR11Ly, SR11Ly1UM171. Hematopoietic stem and progenitor cell (HSPC) expansion, evaluated by flow cytometry and clonogenic assays was compared to either the input HSPCs (Day 0) or the expansion culture without small molecules. For the in vivo experiments, NSG/IL2gnull mice were transplanted with the uncultured inoculum or the total cell output after culture, unless otherwise stated. For more details, see supplemental Methods.
RESULTS AND DISCUSSION
To optimize ex vivo expansion of adult HSCs we tested three modalities (SR1, Ly, and UM171) alone or in certain combinations, but only for a short time in culture to preserve stemness. UM171 alone yielded more phenotypically characterized HSCs compared to the other two small molecules tested alone (Fig. 1A, 1B) . Then, we subsequently combined SR1 and Ly hoping to uncover synergistic and/or additive effects, as inhibition of p38/MAPK is also AHR dependent [8] . This combination achieved similar expansion of HSCs to that of UM171 alone and combination of all three molecules appeared to have an additive effect.
Of interest, under the different protocols apart from the effects on HSC numbers, distinct downstream lineages were enhanced. In UM171 cultures, mainly progenitors with a myeloid bias were enhanced ( Fig. 2A) . By contrast, a high number of megakaryocytic progenitors (Fig. 2B, 2C ), was present in all SR1-containing cultures along with more mature megakaryocytes, even in the absence of TPO and these were completely absent from the UM171 cultures ( Fig. 2D-2F ). Although aryl hydrocarbon pathway repression has been previously shown to promote megakaryocytic specification [9, 10] , the mechanism through which both the megakaryocytic and erythroid differentiation is suppressed by UM171, requires further studies.
Consistent with the phenotypic and CFU culture data ( Fig. 2A-2F ), transcriptomic analysis of cultured cells also uncovered high expression of granulocytic/monocytic genes, and suppression of megakaryocytic/erythroid marker genes in the UM171 cultures; in contrast, cells cultured in the presence of SR11Ly displayed enhanced erythroid/megakaryocytic but suppressed granulocytic/monocytic gene signature (Fig. 2G) . Overall, populations expanded under UM171 or SR11Ly seem to be distinguished by diametrically opposed expression profiles (Fig. 2H) .
The in vivo functional potential of HSCs expanded under different small molecule combinations (UM171, SR11Ly, and SR11Ly1UM171), was tested after transplantation in NSG mice. These mice were transplanted with the entire cultured output generated from the same starting inoculum of CD341 cells. Higher levels of human chimerism were observed in the peripheral blood of mice receiving small molecule-expanded cells compared to the uncultured cells (Fig. 3A) , 4-16 weeks post transplantation, suggesting that a brief 5-day culture period in the presence of small molecules is beneficial. Cells cultured for the same time period only with cytokines, achieved lower engraftment compared to the uncultured cells (Supporting Information Fig. S1 ), as previously reported [11] . However, cells cultured in the presence of SR11Ly exhibited superior engraftment compared to similar total cell numbers of UM171-cells transplanted (Figs. 1A, 3A) . SR11Ly-cells also yielded higher platelet numbers in peripheral blood than all other conditions, 8-weeks post-transplantation, possibly due to the higher numbers of mature megakaryocytes in the inoculum (Fig. 3B) , a feature that could potentially be associated with faster platelet recovery in a transplantation setting. The SR11Ly1UM171 combination, did not further improve the engraftment of the SR11Ly graft (Fig. 3A) , even though contained the highest number of HSCs (Fig. 1A) . Bone marrow studies at week 16, confirmed the robust engraftment of human cells in the SR11Ly (6UM171)-recipients (Fig. 3C) . Multilineage engraftment was detected in every condition. Of note, a significantly lower percentage of CD341 and CD411 cells was detected in the UM171-recipients (Fig.  3D) . Furthermore, the engraftment difference between SR11Ly and UM171 was maintained in secondary recipients (Fig. 3E) .
Our in vivo data so far show that in contrast to expectations the number of ex vivo expanded phenotypic-HSCs under different expansion conditions is not predictive of the engraftment outcome. To explain the different engraftment outcomes, we hypothesized that there either are intrinsic differences among the expanded HSCs, or that the non-HSC, companion cells are responsible. For example, megakaryocytes, that are abound in the SR11Ly cultures, have been implicated in affecting HSC engraftment potential as well as cell cycle, proliferation and differentiation post ablation and transplantation [12] [13] [14] .
To explore the two aforementioned possibilities, we designed a new set of in vivo experiments. We transplanted the same number of sorted CD341/CD38-/CD901 cells, expanded under SR11Ly or UM171, either alone (Fig. 4A ) or in combination with their switched-over non-HSC companion cells (Fig.  4B) . Once again, the SR11Ly-isolated HSCs achieved significantly higher engraftment levels than their numerically and phenotypically similar counterparts under UM171 (Fig. 4C) . Upon addition of alternate companion cells, engraftment differences were maintained suggesting HSC-intrinsic rather than extrinsic effects (Fig. 4D) , although, the theoretical possibility of an indirect effect exerted by the companion cells, shaping intrinsic properties of the HSCs during the 5-day culture, cannot be excluded.
To account for engraftment differences of sorted CD341/ CD38-/CD901 expanded cells, we explored the homing potential of these donor populations. Surface molecule expression revealed no significant differences in any of the adhesion molecules tested (Supporting Information Fig. S2 ). Furthermore, in vivo homing experiments could not uncover a superior homing potential of the SR11Ly HSCs (Fig. 4E) . Instead, a faster and superior in vivo bone marrow expansion potential was documented 12 days post transplantation (Fig. 4F) .
To further explore whether the in vivo functional advantage of SR1Ly versus UM171 expanded HSCs could be associated with their intrinsic transcriptional profile, we performed RNA sequencing of sorted populations (CD341/CD38-/ CD901) expanded under the two different protocols. Surveying the differentially expressed genes, we found that genes involved in the Rap1, Ras, and PI3K-Akt pathways, were significantly downregulated in SR11Ly over UM171 HSCs ( Fig. 4F ; Supporting Information Figs. S3-S5). These three closely regulated pathways play central role in regulating proliferation, apoptosis, differentiation, cell adhesion and metabolism [15] [16] [17] [18] with both complementary and antagonistic cellcontext dependent effects in hematopoiesis [19] . Highly active Rap1 and Ras pathways trigger PI3K and activated PI3K-Akt signaling has been associated with HSC exhaustion and depletion [20] [21] [22] as well as thrombocytopenia [20] , whereas silencing enhances cell engraftment [23] . This latter outcome is consistent with our results with SR11Ly versus UM171 reflecting the enhanced engraftment, of the former.
CONCLUSION
In summary, our data show that adult HSPCs cultured for 5 days in the presence of SR11Ly, achieve post transplantation significantly higher and long-term sustained in vivo engraftment levels compared to cells cultured in the presence of UM171-alone. The transcriptomic profile of ex vivo expanded phenotypically similar HSCs, under different small molecule combinations, uncovers specific functional differences that likely impact their engraftment potential.
